Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.315 USD | +0.72% | -0.71% | -27.99% |
03-27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
03-27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- Analyst Reco.